Atea Pharmaceuticals Overview
- Founded
- 2012
- Status
- Public
- Employees
- 59
- Stock Symbol
- AVIR
- Share Price
- $5.89
- (As of Monday Closing)
Atea Pharmaceuticals General Information
Description
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- 125 Summer Street
- 16th Floor
- Boston, MA 02110
- United States
+1 (857) 000-0000
Atea Pharmaceuticals Timeline
Atea Pharmaceuticals Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.89 | $5.75 | $5.50 - $79.49 | $479M | 83.2M | 1.27M | $1.46 |
Atea Pharmaceuticals Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (96,722) | (96,722) | 3,522,098 | |
| Revenue | 351,367 | 351,367 | 48,633 | 0 |
| EBITDA | 138,406 | 138,406 | (11,011) | (14,591) |
| Net Income | 121,190 | 121,190 | (10,947) | (14,034) |
| Total Assets | 772,892 | 772,892 | 863,632 | 22,073 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Atea Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.
Request a free trialAtea Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.
Request a free trialAtea Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Atea Pharmaceuticals Inc is a clinical stage biopharmaceutical company engaged in discovering and developing therapies t
Drug Discovery
Boston, MA
59
As of 2021
00000
0.000
0000-00-00
00000000
00000
000000 0
quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure d
000000000000000
Foster City, CA
00000
As of 0000
00.000
000000000
00.000
000000 0
n reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000 000000000
Burlingame, CA
00
As of 0000
00000
000000 - 000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialAtea Pharmaceuticals Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | Zurich, Switzerland | 000 | 00000 | 00000000 | 00000 |
| 0000000000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 0000 | 000000 0 | 0000 |
| 000000 00000000000 | Corporation | Plymouth Meeting, PA | 000 | 000.00 | 00000000 | 000.00 |
Atea Pharmaceuticals Patents
Atea Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10874687-B1 | Highly active compounds against covid-19 | Active | 27-Feb-2020 | 00000000000 | 000 |
| US-20210275563-A1 | Highly active compounds against covid-19 | Pending | 27-Feb-2020 | 00000000000 | |
| EP-3897668-A1 | Highly active compounds against covid-19 | Pending | 27-Feb-2020 | 000000000 | |
| US-20200179415-A1 | Highly active drug combination for treatment of hepatitis c virus | Pending | 05-Dec-2018 | 00000000000 | |
| EP-3890751-A1 | Highly active drug combination for treatment of hepatitis c virus | Pending | 05-Dec-2018 | A61K31/685 |
Atea Pharmaceuticals Executive Team (10)
Atea Pharmaceuticals Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bihua Chen | Self | Board Member | 000 0000 |
| Bruce Polsky | Atea Pharmaceuticals | Board Member | 000 0000 |
| Bruno Lucidi | Atea Pharmaceuticals | Board Member | 000 0000 |
| Frank Yu | Self | Board Member | 000 0000 |
| Franklin Berger | Self | Board Member | 000 0000 |
Atea Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAtea Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Atea Pharmaceuticals‘s full profile, request access.
Request a free trial